Search Results

Metrion Biosciences Limited and Enamine Ltd announced that Metrion has enhanced its High Throughput Screening services with the addition of access to Enamine’s compound libraries.

Metrion Biosciences Limited announced that it has secured £3.5m in new equity financing, including £2.5m from lead investor Maven Capital Partners and £1 million from existing investor, Gresham House Ventures.

Metrion Biosciences Limited announced the appointments of Dr Robert Kirby to Chief Operating Officer and Dr Edward Stevens to Chief Scientific Officer.

Metrion Biosciences Limited announced it has received notification from the UK’s Medicines and Healthcare products Regulatory Agency that the Company is now a member of the UK GLP Compliance Monitoring Programme, and is therefore able to offer GLP compliant hERG ion channel screening services to the global life sciences community.

Metrion Biosciences Ltd, the specialist ion channel contract research and drug discovery company, announced the appointment of Dr Steve Jenkinson as Vice President, Drug Discovery and Safety Assessment.

Metrion Biosciences Limited and The KCNC1 Foundation announced a collaboration to progress a hit identification research project for small molecule modulators of the potassium ion channel Kv3.1, targeting KCNC1-related disorders.

Metrion Biosciences Limited, the specialist ion channel contract research and drug discovery company, announced the appointment of Dr Benedetta Montagnini as Head of European Business Development.

Metrion Biosciences Limited, the specialist ion channel contract research and drug discovery company, announced the appointment of Dr Rory Curtis as Vice President US Commercial Operations.

Metrion Biosciences Limited, the specialist ion channel contract research and drug discovery company, announced that the Company has moved to larger, custom designed laboratory and office premises at Granta Park, Cambridge, UK.